São Paulo, May 2025 – Recognized for its history of social initiatives, Eurofarma, a pharmaceutical multinational with 100% Brazilian capital, has joined the Zero Sexual Violence Movement (Movimento Violência Sexual Zero), which strengthens awareness practices to combat sexual violence against children and adolescents.

The initiative, which already brings together around 100 companies, emerged as a response to the fact that eight¹ children and adolescents are victims of sexual violence every hour in Brazil, with the vast majority of these cases going unreported. According to estimates, only 8.5%² of all rape cases are reported; considering only those reported, 80%³ of the victims are under 18 years old. Faced with these alarming figures, the movement's proposal is to distribute educational materials to the employees of participating companies, strengthening prevention and the confrontation of this reality.

The partnership will support internal initiatives to reinforce guidelines for identifying cases, encourage reporting, and establish support and welcoming protocols for cases of abuse. This membership is in synergy with one of Eurofarma's main pillars of social action, the Eurofarma Institute, which for 19 years has offered various opportunities and programs for children and adolescents, focusing on education, professional qualification, and personal development.

The company is a signatory to the Global Compact, a United Nations (UN) initiative that helps promote corporate sustainability. It also contributes to the UN 2030 Agenda, having Quality Education as one of the priority Sustainable Development Goals (SDG) in its operations.

¹'³ IPEA 2023 Research
² 2024 Brazilian Public Security Yearbook

About Eurofarma
Founded in 1972, Eurofarma operates in the healthcare sector, producing and marketing products and services to improve people's quality of life. Focused on shared value generation, it covers key pharmaceutical segments such as prescription drugs, OTC and personal care, generics, hospital, oncology, and animal health, in addition to providing third-party manufacturing services. With broad coverage across therapeutic classes, the portfolio comprises over 4,000 SKUs, serving major medical specialties. A leader in medical prescriptions in Brazil, where it holds the second position in generics, Eurofarma is present in 24 countries, with 100% coverage in Latin America and operations in the USA and Africa. It has 13,300 employees and 11 manufacturing plants, with a total production of 600 million units in 2024. In the same year, it invested over R$ 800 million in innovation projects and achieved a total net revenue of R$ 11 billion.

Press Information
G&A Relações Públicas
e-mail: imprensaeurofarma@gaspar.com.br
Iza França - +55 11 97644-4496 (iza.franca@gaspar.com.br) 
Guilherme Gaspar - +55 11 98285-6000